Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 6/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594167 | 1.00 | CRHBP (0.43) | CRHBPCRHR2CPA1CES2CES1 | |
| SCHEMBL4088187 | 0.86 | CPA3 (0.42) | CRHBPCRHR2CPA1CES2CES1 | |
| SCHEMBL4088184 | 0.86 | CPA3 (0.42) | CRHBPCRHR2CPA1CES2CES1 | |
| SCHEMBL20856984 | 0.81 | FNTA (0.47) | CRHBPCRHR2CPA1 | |
| SCHEMBL16599213 | 0.80 | EPOR (0.47) | CRHBPCRHR2CPA1 | |
| SCHEMBL16599212 | 0.80 | EPOR (0.47) | CRHBPCRHR2CPA1 | |
| SCHEMBL20522200 | 0.78 | KDM6B (0.47) | CRHBPCRHR2CPA1 | |
| SCHEMBL20522201 | 0.78 | KDM6B (0.47) | CRHBPCRHR2CPA1 | |
| SCHEMBL3126205 | 0.76 | KMT2A (0.49) | ALDH1A1LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL2855957 | 0.76 | KMT2A (0.49) | ALDH1A1LMNAMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807515-A4 | ORTHOGONAL TRANSLATION COMPONENTS FOR THE IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | SCRIPPS RESEARCH INST (US) | 2008-06-18 | — | — | EP | claimed |
| EP-1807515-A2 | ORTHOGONAL TRANSLATION COMPONENTS FOR THE IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | The Scripps Research Institute (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006110182-A2 | ORTHOGONAL TRANSLATION COMPONENTS FOR THE IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-10-19 | — | — | WO | claimed |
| CN-1095069-A | Novel process for the preparation and/or purification of clavulanic acid or pharmaceutically acceptable salts or esters thereof | SMITHKLINE BEECHAM PLC (GB) | 1994-11-16 | — | — | CN | claimed |
| US-20250376709-A1 | PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL | UNIV UTAH RES FOUND (US) | 2025-12-11 | — | — | US | disclosed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025085727-A1 | PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL | BANDARIAN VAHE (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085723-A1 | THIOETHER CROSSLINKS IN C-TERMINAL AND N-TERMINAL MODIFIED PEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4508235-A2 | PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL | University of Utah Research Foundation (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119410678-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119410679-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-1258298-A | Process for preparation of metal salt of clavulanic acid | SMITHKLINE BEECHAM PLC (GB) | 2000-06-28 | — | — | CN | disclosed |
| CN-1041934-C | Novel process | SMITHKLINE BEECHAM PLC (GB) | 1999-02-03 | — | — | CN | disclosed |
| CN-1179161-A | Clavulanic acid extractim process | SMITHKLINE BEECHAM PLC (GB) | 1998-04-15 | — | — | CN | disclosed |
| CN-1037967-C | novel intermediates and their use for the preparation of clavulanic acid | SMITHKLINE BEECHAM PLC (GB) | 1998-04-08 | — | — | CN | disclosed |
| CN-1036592-C | Novel method for preparation and/or purification of clavulanic acid or pharmaceutical salt or ester of same | SMITHKLINE BEECHAM PLC (GB) | 1997-12-03 | — | — | CN | disclosed |
| CN-1113244-A | Novel process | SMITHKLINE BEECHAM PLC (GB) | 1995-12-13 | — | — | CN | disclosed |
| CN-1112928-A | Novel method for preparation and/or purification of clavulanic acid or pharmaceutical salt or ester of same | SMITHKLINE BEECHAM PLC (GB) | 1995-12-06 | — | — | CN | disclosed |
| CN-1095069-A | Novel process for the preparation and/or purification of clavulanic acid or pharmaceutically acceptable salts or esters thereof | SMITHKLINE BEECHAM PLC (GB) | 1994-11-16 | — | — | CN | disclosed |